Skip to main content
NYSE:CC

The Chemours Competitors

$34.87
+0.16 (+0.46 %)
(As of 05/18/2021 09:31 AM ET)
Add
Compare
Today's Range
$34.87
$34.96
50-Day Range
$27.43
$34.65
52-Week Range
$11.98
$35.53
Volume801 shs
Average Volume1.44 million shs
Market Capitalization$5.77 billion
P/E RatioN/A
Dividend Yield2.97%
Beta2.3

Competitors

The Chemours (NYSE:CC) Vs. FMC, OLN, HUN, ASH, UNVR, and GRA

Should you be buying CC stock or one of its competitors? Companies in the industry of "chemicals & allied products" are considered alternatives and competitors to The Chemours, including FMC (FMC), Olin (OLN), Huntsman (HUN), Ashland Global (ASH), Univar Solutions (UNVR), and W. R. Grace & Co. (GRA).

The Chemours (NYSE:CC) and FMC (NYSE:FMC) are both basic materials companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Volatility and Risk

The Chemours has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500. Comparatively, FMC has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

Earnings & Valuation

This table compares The Chemours and FMC's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Chemours$5.53 billion1.04$-52,000,000.00$2.5113.89
FMC$4.61 billion3.31$477.40 million$6.0919.44

FMC has lower revenue, but higher earnings than The Chemours. The Chemours is trading at a lower price-to-earnings ratio than FMC, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares The Chemours and FMC's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Chemours-2.35%46.27%4.51%
FMC10.64%30.81%8.57%

Analyst Recommendations

This is a summary of recent ratings and target prices for The Chemours and FMC, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Chemours04402.50
FMC05902.64

The Chemours currently has a consensus target price of $31.3750, suggesting a potential downside of 9.61%. FMC has a consensus target price of $130.00, suggesting a potential upside of 9.78%. Given FMC's stronger consensus rating and higher possible upside, analysts clearly believe FMC is more favorable than The Chemours.

Insider & Institutional Ownership

74.7% of The Chemours shares are owned by institutional investors. Comparatively, 87.4% of FMC shares are owned by institutional investors. 2.7% of The Chemours shares are owned by insiders. Comparatively, 1.0% of FMC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dividends

The Chemours pays an annual dividend of $1.00 per share and has a dividend yield of 2.9%. FMC pays an annual dividend of $1.92 per share and has a dividend yield of 1.6%. The Chemours pays out 39.8% of its earnings in the form of a dividend. FMC pays out 31.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. The Chemours has increased its dividend for 1 consecutive years and FMC has increased its dividend for 1 consecutive years.

Summary

FMC beats The Chemours on 11 of the 16 factors compared between the two stocks.

Olin (NYSE:OLN) and The Chemours (NYSE:CC) are both mid-cap basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Olin and The Chemours, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olin04902.69
The Chemours04402.50

Olin currently has a consensus price target of $43.1538, suggesting a potential downside of 8.24%. The Chemours has a consensus price target of $31.3750, suggesting a potential downside of 9.61%. Given Olin's stronger consensus rating and higher probable upside, equities research analysts plainly believe Olin is more favorable than The Chemours.

Institutional & Insider Ownership

84.7% of Olin shares are held by institutional investors. Comparatively, 74.7% of The Chemours shares are held by institutional investors. 11.7% of Olin shares are held by company insiders. Comparatively, 2.7% of The Chemours shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Olin has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, The Chemours has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500.

Valuation & Earnings

This table compares Olin and The Chemours' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olin$6.11 billion1.23$-11,300,000.00$0.6078.33
The Chemours$5.53 billion1.04$-52,000,000.00$2.5113.89

Olin has higher revenue and earnings than The Chemours. The Chemours is trading at a lower price-to-earnings ratio than Olin, indicating that it is currently the more affordable of the two stocks.

Dividends

Olin pays an annual dividend of $0.80 per share and has a dividend yield of 1.7%. The Chemours pays an annual dividend of $1.00 per share and has a dividend yield of 2.9%. Olin pays out 133.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. The Chemours pays out 39.8% of its earnings in the form of a dividend. Olin has increased its dividend for 1 consecutive years and The Chemours has increased its dividend for 1 consecutive years. The Chemours is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Olin and The Chemours' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olin-18.47%-9.98%-2.34%
The Chemours-2.35%46.27%4.51%

Summary

Olin beats The Chemours on 9 of the 16 factors compared between the two stocks.

Huntsman (NYSE:HUN) and The Chemours (NYSE:CC) are both mid-cap basic materials companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Huntsman and The Chemours, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Huntsman031202.80
The Chemours04402.50

Huntsman currently has a consensus target price of $30.6875, indicating a potential upside of 3.29%. The Chemours has a consensus target price of $31.3750, indicating a potential downside of 9.61%. Given Huntsman's stronger consensus rating and higher possible upside, research analysts plainly believe Huntsman is more favorable than The Chemours.

Profitability

This table compares Huntsman and The Chemours' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Huntsman16.55%5.27%2.06%
The Chemours-2.35%46.27%4.51%

Dividends

Huntsman pays an annual dividend of $0.65 per share and has a dividend yield of 2.2%. The Chemours pays an annual dividend of $1.00 per share and has a dividend yield of 2.9%. Huntsman pays out 42.5% of its earnings in the form of a dividend. The Chemours pays out 39.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Huntsman has increased its dividend for 1 consecutive years and The Chemours has increased its dividend for 1 consecutive years. The Chemours is clearly the better dividend stock, given its higher yield and lower payout ratio.

Earnings & Valuation

This table compares Huntsman and The Chemours' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Huntsman$6.80 billion0.97$562 million$1.5319.49
The Chemours$5.53 billion1.04$-52,000,000.00$2.5113.89

Huntsman has higher revenue and earnings than The Chemours. The Chemours is trading at a lower price-to-earnings ratio than Huntsman, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

77.3% of Huntsman shares are held by institutional investors. Comparatively, 74.7% of The Chemours shares are held by institutional investors. 5.4% of Huntsman shares are held by company insiders. Comparatively, 2.7% of The Chemours shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Huntsman has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, The Chemours has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500.

Summary

Huntsman beats The Chemours on 9 of the 16 factors compared between the two stocks.

Ashland Global (NYSE:ASH) and The Chemours (NYSE:CC) are both mid-cap basic materials companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Ashland Global and The Chemours' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ashland Global-21.84%5.40%2.43%
The Chemours-2.35%46.27%4.51%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Ashland Global and The Chemours, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ashland Global10702.75
The Chemours04402.50

Ashland Global currently has a consensus price target of $92.4444, indicating a potential upside of 3.15%. The Chemours has a consensus price target of $31.3750, indicating a potential downside of 9.61%. Given Ashland Global's stronger consensus rating and higher probable upside, analysts clearly believe Ashland Global is more favorable than The Chemours.

Earnings & Valuation

This table compares Ashland Global and The Chemours' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ashland Global$2.33 billion2.33$-508,000,000.00$2.8031.92
The Chemours$5.53 billion1.04$-52,000,000.00$2.5113.89

The Chemours has higher revenue and earnings than Ashland Global. The Chemours is trading at a lower price-to-earnings ratio than Ashland Global, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

91.9% of Ashland Global shares are owned by institutional investors. Comparatively, 74.7% of The Chemours shares are owned by institutional investors. 10.1% of Ashland Global shares are owned by company insiders. Comparatively, 2.7% of The Chemours shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Ashland Global has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Comparatively, The Chemours has a beta of 2.3, meaning that its stock price is 130% more volatile than the S&P 500.

Dividends

Ashland Global pays an annual dividend of $1.10 per share and has a dividend yield of 1.2%. The Chemours pays an annual dividend of $1.00 per share and has a dividend yield of 2.9%. Ashland Global pays out 39.3% of its earnings in the form of a dividend. The Chemours pays out 39.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Ashland Global has raised its dividend for 1 consecutive years and The Chemours has raised its dividend for 1 consecutive years.

Summary

Ashland Global beats The Chemours on 9 of the 16 factors compared between the two stocks.

The Chemours (NYSE:CC) and Univar Solutions (NYSE:UNVR) are both mid-cap basic materials companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Profitability

This table compares The Chemours and Univar Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Chemours-2.35%46.27%4.51%
Univar Solutions0.38%12.65%3.32%

Insider and Institutional Ownership

74.7% of The Chemours shares are owned by institutional investors. Comparatively, 98.6% of Univar Solutions shares are owned by institutional investors. 2.7% of The Chemours shares are owned by company insiders. Comparatively, 1.6% of Univar Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares The Chemours and Univar Solutions' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Chemours$5.53 billion1.04$-52,000,000.00$2.5113.89
Univar Solutions$9.29 billion0.49$-100,200,000.00$1.4019.12

The Chemours has higher earnings, but lower revenue than Univar Solutions. The Chemours is trading at a lower price-to-earnings ratio than Univar Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for The Chemours and Univar Solutions, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Chemours04402.50
Univar Solutions11102.00

The Chemours currently has a consensus target price of $31.3750, suggesting a potential downside of 9.61%. Univar Solutions has a consensus target price of $26.75, suggesting a potential downside of 0.07%. Given Univar Solutions' higher possible upside, analysts plainly believe Univar Solutions is more favorable than The Chemours.

Risk and Volatility

The Chemours has a beta of 2.3, meaning that its stock price is 130% more volatile than the S&P 500. Comparatively, Univar Solutions has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.

Summary

The Chemours beats Univar Solutions on 9 of the 14 factors compared between the two stocks.

The Chemours (NYSE:CC) and W. R. Grace & Co. (NYSE:GRA) are both mid-cap basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Volatility & Risk

The Chemours has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500. Comparatively, W. R. Grace & Co. has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares The Chemours and W. R. Grace & Co.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Chemours-2.35%46.27%4.51%
W. R. Grace & Co.0.76%55.80%5.10%

Insider and Institutional Ownership

74.7% of The Chemours shares are owned by institutional investors. Comparatively, 84.8% of W. R. Grace & Co. shares are owned by institutional investors. 2.7% of The Chemours shares are owned by insiders. Comparatively, 0.9% of W. R. Grace & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

The Chemours pays an annual dividend of $1.00 per share and has a dividend yield of 2.9%. W. R. Grace & Co. pays an annual dividend of $1.32 per share and has a dividend yield of 1.9%. The Chemours pays out 39.8% of its earnings in the form of a dividend. W. R. Grace & Co. pays out 30.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. The Chemours has raised its dividend for 1 consecutive years and W. R. Grace & Co. has raised its dividend for 1 consecutive years.

Analyst Recommendations

This is a summary of current ratings and target prices for The Chemours and W. R. Grace & Co., as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Chemours04402.50
W. R. Grace & Co.06202.25

The Chemours currently has a consensus target price of $31.3750, indicating a potential downside of 9.61%. W. R. Grace & Co. has a consensus target price of $66.8571, indicating a potential downside of 2.41%. Given W. R. Grace & Co.'s higher probable upside, analysts clearly believe W. R. Grace & Co. is more favorable than The Chemours.

Valuation and Earnings

This table compares The Chemours and W. R. Grace & Co.'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Chemours$5.53 billion1.04$-52,000,000.00$2.5113.89
W. R. Grace & Co.$1.96 billion2.32$126.30 million$4.3815.64

W. R. Grace & Co. has lower revenue, but higher earnings than The Chemours. The Chemours is trading at a lower price-to-earnings ratio than W. R. Grace & Co., indicating that it is currently the more affordable of the two stocks.

Summary

W. R. Grace & Co. beats The Chemours on 10 of the 16 factors compared between the two stocks.


The Chemours Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
FMC logo
FMC
FMC
1.9$118.42+0.2%$15.26 billion$4.61 billion31.00Analyst Revision
Olin logo
OLN
Olin
1.6$47.00+0.1%$7.50 billion$6.11 billion-7.31
Huntsman logo
HUN
Huntsman
2.3$29.82+0.4%$6.59 billion$6.80 billion6.72Analyst Report
Ashland Global logo
ASH
Ashland Global
1.8$89.37+0.3%$5.44 billion$2.33 billion-10.64
Univar Solutions logo
UNVR
Univar Solutions
1.0$26.77+0.8%$4.58 billion$9.29 billion148.73Analyst Upgrade
W. R. Grace & Co. logo
GRA
W. R. Grace & Co.
2.2$68.51+0.2%$4.54 billion$1.96 billion326.24
Balchem logo
BCPC
Balchem
1.6$131.01+1.7%$4.25 billion$643.71 million51.38Analyst Downgrade
Ingevity logo
NGVT
Ingevity
1.7$89.18+0.3%$3.58 billion$1.29 billion20.69
Livent logo
LTHM
Livent
1.3$17.15+0.2%$2.52 billion$388.40 million-190.56
Innospec logo
IOSP
Innospec
1.8$100.26+0.7%$2.47 billion$1.51 billion67.29Analyst Downgrade
PQ Group logo
PQG
PQ Group
1.7$16.05+3.7%$2.20 billion$1.57 billion50.16Analyst Report
High Trading Volume
GCP Applied Technologies logo
GCP
GCP Applied Technologies
1.5$26.39+1.0%$1.94 billion$1.01 billion18.33
Hawkins logo
HWKN
Hawkins
2.0$33.00+0.8%$700.33 million$540.20 million10.51Upcoming Earnings
Loop Industries logo
LOOP
Loop Industries
1.4$7.81+0.8%$331.25 millionN/A-18.60News Coverage
GURE
Gulf Resources
0.6$7.26+2.2%$74.19 million$10.60 million0.00News Coverage
Gap Down
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.